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ChildWe compared the microbiology of middle ear fluid (MEF) in two cohorts of children having ventilation
tube (VT) insertion; the first in the era of 7-valent Streptococcus pneumoniae conjugate vaccine (PCV7)
and the second following introduction of the ten-valent pneumococcal vaccine (PHiD-CV10).
Methods: During 2011 (Phase 1) and again in 2014 (Phase 2) MEF and NP samples from 325 children and
319 children were taken at the time of VT insertion. A matched comparison group had NP swabs collected
with 137 children (Phase 1) and 154 (Phase 2). Culture was performed on all NP and MEF samples with
further molecular identification of Haemophilus species, serotyping of S. pneumoniae, and polymerase
chain reaction (PCR) testing on all MEF samples.
Results: In Phase 2 immunisation coverage withP3 doses of PHiD-CV10 was 93%. The rate and ratios of
culture and molecular detection of the 3 main otopathogens was unchanged between Phase 1 and Phase
2 in both MEF and NP. Haemophilus influenzae was cultured in one quarter and detected by PCR in 53% of
MEF samples in both time periods. S. pneumoniae andMoraxella catarrhaliswere cultured in up to 13% and
detected by PCR in 27% and 40% respectively of MEF samples. H. influenzae was the most common organ-
ism isolated from NP samples (61%) in the children undergoing VT surgery whilstM. catarrhalis (49%) was
the most common in the non-otitis prone group. 19A was the most prominent S. pneumoniae serotype in
both MEF and NP samples in Phase 2. Of Haemophilus isolates, 95% were confirmed to be non-typeable
H. influenzae (NTHi) over both time periods.
Conclusion: Following implementation of PHiD-CV10 in New Zealand, there has been no significant
change in the 3 major otopathogens in NP or MEF in children with established ear disease. For these chil-
dren non-typeable H. influenzae remains the dominant otopathogen detected.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Otitis media (OM) remains one of the most common disorders
for which medical care is sought in childhood and a common rea-
son for prescribing antibiotics [1]. Ventilation tube insertion (VT) is
the most frequent surgical procedure performed in young children,
with recurrent AOM (rAOM) and persistent otitis media with effu-
sion (OME) being the usual indications. Worldwide, parents report
that otitis media can be a significant burden on their family [2].
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lead to reductions in antibiotic prescribing [3], have beneficial
economic effects by reducing primary care visits and time off work
for parents as well as reduce complications of acute otitis media
such as perforations and numbers of children requiring VT [4].
The established primary bacterial otopathogens are Streptococ-
cus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis,
which colonise the nasopharynx prior to invasion into the middle
ear [5]. S. pneumoniae is the only vaccine preventable pathogen
of OM due to available pneumococcal conjugate vaccines. Yet
introduction of a 7-valent pneumococcal conjugate vaccine
(PCV7; Prevenar) to infant vaccination schedules in many devel-
oped countries had a relatively small effect on AOM. A Cochrane
review of evidence concluded PCV7 to have modest benefit in
reduction of AOM in healthy infants and no benefit for high-risk
infants and older children with a history of AOM [6]. Post
marketing surveillance has showed declines in rates of VT insertion
of 6–23% in <2 year olds in Australia [7] and by up to 20% in certain
states in the US [8] suggesting some impact on recurrent or
persistent ear disease. These reductions may be explained by
reduction in vaccine-related pneumococcal serotypes causing
disease, yet the modest effects overall could be due to an increase
in non-vaccine S. pneumoniae serotypes and/or replacement
with other pathogens [9–11]. Furthermore, measuring vaccine
effectiveness with otitis media as an end point is fraught with
difficulty, due to the multifactorial pathogenesis of otitis media,
variability in diagnosis, and the spectrum of OM disease. Other
confounders such as variability in health seeking behaviour within
a population, public health measures, antibiotic use and other
vaccine implementations can occur simultaneously and also
impact on OM outcomes creating challenges in measuring PCVs
true impact [12].
In New Zealand (NZ), PCV7 was introduced as a 3 + 1 schedule
in 2008 and significantly decreased the burden of invasive pneu-
mococcal disease (IPD) caused by PCV7 serotypes in young chil-
dren [13]. There was also evidence of impact on non-invasive
diseases such as childhood hospitalisations from pneumonia [14]
and indirect (herd) effects leading to reductions in IPD due to
PCV7 serotypes in older age groups [13]. Phase one of our study
commenced in 2011, three years after PCV7 introduction in NZ.
We collected middle ear fluid (MEF) and NP samples from children
presenting for VT insertion [15]. Following completion of this
study, in late 2011, the national immunisation schedule was
revised with replacement of PCV7 with the 10-valent pneumococ-
cal conjugate vaccine (PHiD-CV10) [16]. This vaccine covers 3 addi-
tional serotypes of S. pneumoniae, but of particular interest in otitis
media prevention is use in PHiD-CV10 of protein D from H. influen-
zae as the conjugating protein for 8 of the included 10 S. pneumo-
niae serotypes. A pre-licensure randomised controlled trial using
an 11-valent PCV containing a related protein D (11PnPD) demon-
strated efficacy preventing AOM; both due to vaccine type S. pneu-
moniae but also due to H. influenzae when compared with placebo
[17]. However there is little support for any impact on nasopharyn-
geal prevalence or density of H. influenzae carriage following vacci-
nation and no post-licensure evidence for impact on recurrent
AOM or AOM specifically due to H. influenzae [18,19].
With the opportunity provided by NZ’s changing pneumococcal
vaccine schedule, we aimed to describe and compare the aetiology
of otitis media with specific attention to changes in the microbiol-
ogy of MEF and NP carriage, including S. pneumoniae serotypes and
H. influenzae prior to and following implementation of PHiD-CV10.
In addition we aimed to document and compare the nasopharyn-
geal carriage and antibiotic susceptibility of organisms known to
cause OM in children with and without a history of rAOM or
OME in PCV7 and PHiD-CV10 vaccine eras.2. Materials and methods
Children aged less than 36 months of age undergoing VT were
recruited from the three major referral centres in New Zealand
for children undergoing VT for rAOM or OME: two in Auckland
and one in Christchurch. Recruitment occurred between May to
November, 2011 (Phase 1) and May to November, 2014 (Phase
2). In these centres the surgical criteria for VT insertion isP6 epi-
sodes of AOM in 12 months (recurrent AOM) or persistent bilateral
middle ear effusions for >3 months (OME). Diagnosis was made by
trained practitioners, together with micro-otoscopy +/ tympa-
nometry prior to booking for surgery.
In each centre a seasonally matched comparison group of non-
otitis prone children of same age and vaccination eligibility was
also recruited [15]. From parental history they had no significant
previous ear disease (<3 episodes of AOM in 12 months, no history
of OME). These children were having a general anaesthetic for non-
ear related procedures (such as radiologic imaging, general or non-
ear related day surgery). NP swabs were collected from this group.
Children with known immune deficiency, cystic fibrosis or cranio-
facial malformation were excluded from both groups.
Informed consent was obtained prior to procedures. Risk factors
for ear disease and epidemiological data collected via parental/-
carer questionnaire at the time of surgery. Ethnicity was assigned
using a standard priority system [20].
Ethical approval was obtained from the New Zealand Northern
Regional Ethics Committee (NTX/11/04/029).
All children enrolled were eligible for 3 + 1 pneumococcal con-
jugate vaccination (PCV7 in the first cohort, 2011; and PHiD-CV10
in the second cohort, 2014) and H. influenzae type b vaccinations
as part of the national immunisation schedule. Receipt of PCV
was recorded and confirmed for each child using the National
Immunisation Register and/or primary care practice records. Chil-
dren vaccinated solely with PCV13 (which was available for pri-
vate purchase) were actively excluded if that information was
available at enrolment.
2.1. Laboratory method for nasopharyngeal and middle ear samples
Laboratory methods were identical for Phase 1 and 2 and have
been described previously [15]. Middle ear fluid (MEF) was col-
lected by sterile suction through the myringotomy prior to VT
placement, and nasopharyngeal (NP) swabs were collected from
surgical and comparison groups.
MEF was cultured for bacterial pathogens by standard methods
including extended culture to detect Alloiococcus otitidis [21].
S. pneumoniae, H. influenzae and M. catarrhalis isolates were tested
for susceptibility to standard antimicrobials by agar disc diffusion.
Pneumococcal capsular serotyping was performed via Quellung
reaction at the national reference laboratory. From 2014, factor
sera were available to identify serotype 35A and serotypes 15
and 16. All S. pneumoniae isolates from both Phase 1 and 2 had
serotyping repeated to classify these.
For nucleic acid extraction and polymerase chain reactions
200 lL of MEF and 5.0 lL of internal control DNA were extracted
with EasyMag (BioMerieux, Auckland, NZ) generic 2.0.1 protocol.
Nucleic acid was recovered in 60 lL of elution buffer. PCR reac-
tions were based on the Real-time TaqMan PCR format with
S. pneumoniae [22] performed as a duplex with an internal control
(un-published assay) while H. influenzae [23] and M. catarrhalis
[24] were detected using single-plex PCR assay (Supplemental
Table 1).
Differentiation between H. influenzae and Haemophilus
haemolyticus was performed using absence or presence of the
hpd#3 gene by PCR [25]. Samples identified as H. influenzae by
Table 1
Demographic data from children aged less than 3 years undergoing ventilation tube insertion and comparison group: Phase 1, 2011 and Phase 2, 2014.
Children undergoing ventilation tube
insertion
Non-otitis prone comparison aP values
Phase 1 Phase 2 Phase 1 Phase 2
Total number 325 319 137 154
Median age: months (interquartile range) 21.6 (16.9–27.4) 22.6 (16.9–27.3) 21.1 (15.1–29.9) 17.6 (10.8–27.3) <0.001
Male (%) 203 (62) 218 (68) 98 (72) 101 (66) 0.56
Median birth weight: kg (interquartile range) 3.45 (3.09–3.85) 3.55 (3.10–3.85) 3.40 (2.85–3.83) 3.44 (2.91–3.76) 0.15
Gestational age: number less than 38 weeks (%) 52 (16) 56/315 (18) 32 (23) 29/144 (20) 0.06
Child has history of atopy (%) 61/323 (19) 58/318 (18) 19 (14) 20/145 (14) 0.20
Family has history of ear disease (%) 155 (48) 169 (53) 29 (12) 33/145 (23) <0.01
Ethnicity
European 58% 54% 45% 42% <0.05
Maori 22% 24% 18% 26% 0.51
Pacific Island 12% 12% 15% 10% 0.68
Other 8% 10% 23% 22% <0.01
Vaccination status (%)
3 or more doses of PCV at enrolment 315 (96) 301 (94) 129 (93.5) 145 (94) 0.93
Received only PCV10 – 289 (91) – 141 (92) 0.73
Up to dateb 299 (92) 304 (95) 123 (89) 144 (94) 0.42
Environmental factors (%)
Ever breastfed 281/324 (87) 279/319 (87) 116/137 (85) 129/143 (90) 0.56
Exposure to household smoke 101/324 (31) 91/317 (29) 43/136 (31) 39/143 (27) 0.93
Day care attendance (>4 h/week) 205/322 (64) 235/318 (73) 54/134 (40) 40/146 (26) <0.01
Child has P1 sibling 226/324 (70) 229/311 (74) 88/136 (65) 97/129 (75) 0.29
>5 people in home 59/325 (18) 53/319 (17) 23/137 (17) 37/144 (26) 0.76
Antibiotic use (month prior to surgery) 198/321 (62) 159/313 (51) 51/133 (38) 40/146 (27) <0.01
Significant P values in bold text.
a P values represent difference between children undergoing ventilation tube insertion compared with non-otitis prone group within Phase 2 (Phase 1 data published
previously).
b Up to date – received age-appropriate number of doses of pneumococcal vaccine by date of surgery (3 doses if aged over 5 months and up to end of 15th month; and 4
doses if age over 16 months).
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gene PCR [26].
2.2. Sample size calculation
Sample size calculations were performed prior to Phase 1 and
were based on potential change in the proportion of children
with H. influenzae MEF infection pre and post introduction of
PHiD-CV10. We hypothesized there would be a reduction in
proportions of H. influenzae isolated from MEF samples between
Phase 1 (PCV 7 vaccinated cohort) and Phase 2 (PHiD-CV10
vaccinated cohort). We elected to use a conservative estimate of
vaccine efficacy at 20% for prevention of otitis media based on
reported vaccine efficacy against H. influenzae AOM of 35% [17].
Available reported rates of MEF culture for H. influenzae were
16% in a cohort of New Zealand children with OME [27] and
PCR detection rates of 29% in another OME cohort [28]. For
H. influenzae detection rate of 25% a sample of 300 pre-vaccine
and 300 post-vaccine would be required to detect a 20% reduction
in H. influenzae infections at the 5% level of confidence with 90%
power.
2.3. Statistical analyses
Demographic and response data was compared between study
cohorts using odds ratios (comparison of proportions between the
two groups), t-tests (for comparison of continuous variables
between the two groups) and chi-squared tests (for comparing dis-
tributions of the two groups). Detection ofMEF organismswas anal-
ysedwith respect to NP organisms usingMcNemar change test with
continuity correction (to allow for matched nature of data). Confi-
dence intervals generated were at 95% level, with p-value of 0.05
as cut-off. Analysis used R software package version 2.15.2 [29].3. Results
3.1. Study population
In Phase I 462 children were recruited (325 in the VT group and
137 in non-otitis prone group) representing 78% of all VT surgery
performed in this age group in the 3 centres. In Phase 2, 473
children were recruited (319 in the VT surgical group and 154
in the non-otitis prone comparison group) representing 77% of
all children presenting to these centres for VT surgery.
Non-participation was predominantly due to missed recruitment
(patients not captured at the time of surgery) and fewer than 2%
declined to participate.
Baseline demographic and clinical data between phases were
not significantly different. There was a male predominance (over
60%) in both VT and comparison groups in both phases, with an
average age of around 21 months. The significant differences noted
in Phase 1 between children undergoing VT surgery and non-otitis
prone comparison group were also present in Phase 2 (Table 1)
with children undergoing VT surgery being more likely to attend
day-care, have a family history of ear disease, and have had antibi-
otics in the past month. Information on antibiotic usage was avail-
able for 98% of all participants. Recent antibiotic use was high in
both groups, with amoxycillin being the most commonly used
antibiotic (in both time periods). In both phases the otitis-prone
children were more likely to have received antibiotics at a doctor’s
(parental report) on >5 occasions in the prior 12 months (46% and
51%) compared to children in the comparison groups (1% and 0%).
3.2. Vaccination status
The vast majority of the children had received 3 ormore doses of
PCV at study entry in both phases (Table 1). A small proportion of
Table 2
Comparison of surgical indication and findings at surgery between two cohorts of children aged less than 3 years undergoing ventilation tube insertion: Phase 1, 2011 & Phase 2,
2014.
Ventilation tube patients Phase 1 (2011) Phase 2 (2014) p value: Phase 1 vs 2
N = 325 N = 319
Surgical indication at time of referral Otitis media with effusion 32% 29% 0.39
Recurrent AOM 29% 45% <0.05
Acute symptoms and OME 37% 26% <0.05
Other (tympanic membrane retraction) 2% <1% 0.10
Middle ear findings at surgery (%)
Bilateral dry tap 70 (21.5) 87 (27) 0.09
Unilateral dry tap 71 (22) 63 (20) 0.51
Bilateral effusion 184 (57) 169 (53) 0.35
Fluid in one or both ears 255 (78.5) 232 (73) 0.09
Number of MEF examined N = 441 N = 401
Gross description of surgical findings when fluid identified (%) Mucoid/thick 265 (60) 266 (66) 0.06
Mucopus 86 (19.5) 54 (13.5) <0.05
Serous/thin 88 (20) 81 (20) 0.93
Significant P values in bold text.
Table 3
Culture and polymerase chain reaction detection of otopathogens from middle ear fluid of two cohorts of children aged less than 3 years undergoing ventilation tube insertion:
Phase 1, 2011 & Phase 2, 2014.
Phase 1: 2011
N = 255 (428)a
Phase 2: 2014
N = 232 (388)a
p value: Phase 1 vs 2
Culture positive (% of patients) Streptococcus pneumoniae 26 (10) 24 (10) 0.96
Haemophilus influenzae 63 (25) 65 (28) 0.41
Moraxella catarrhalis 26 (10) 31 (13) 0.28
PCR detection (% samples) Streptococcus pneumoniae 104 (24) 104 (27) 0.43
Haemophilus influenzae 227 (53) 205 (53) 0.92
Moraxella catarrhalis 182 (43) 156 (40) 0.48
a N = number of children with unilateral or bilateral positive MEF samples (number of samples collected).
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surgical groups (Phase 1: 3% and Phase 2: 1%) and comparison
groups (3% both phases) which did not significantly change over
time periods. In Phase II over 93% of children had received at least
3 doses of PHiD-CV10, and 15 of the 319 children (5%) having VT
insertion had received less than 3 doses (1 received no PHiDCV10
doses, 7 received one dose and 7 received 2 doses). Amongst
the comparison group, 5 children received less than 3 doses of
PHiD-CV10 with 4 having had only 1 dose of PHiD-CV10 and 1
received 2 doses. No children received PCV13 in Phase 1 and in
Phase 2, 12 children (2.5%) received 1 or more doses of PCV13.
Overall children in Phase 2 were more likely to be up to date
with pneumococcal vaccination compared with Phase 1 (odds ratio
0.57, 95% CI 0.34, 0.96).
All recruited children were included in analysis regardless of
vaccination status.3.3. Surgical indication
The proportion of children requiring ventilation tubes for per-
sistent middle ear effusions (OME) remained the same between
time periods. The primary indication for VT surgery changed
between time periods with more children identified as rAOM
(29% Phase 1 compared with 45% Phase 2) rather than acute symp-
toms with persistent middle ear fluid (37% Phase 1 versus 26%
Phase 2) (Table 2). Macroscopic findings at time of surgery showed
less children observed to have MEF described as ‘mucopus’ in the
later cohort (19.5% Phase 1 versus 13.5% Phase 2; p =< 0.05).3.4. Microbiology: middle ear fluid
In Phase 2, amongst the 319 children having ventilation tubes,
87 had no MEF bilaterally (27%), giving 232 children with MEF in
one or both ears and 401 MEF samples collected. Thirteen samples
(3%) were unprocessed thus 388 samples from 232 patients with
bilateral or unilateral MEF were cultured and had PCR in Phase 2.
This compared with 441 samples being collected from 255 children
in Phase 1, with 428 of these available to process (Table 3).
Comparison between phases of the three main otopathogens in
MEF by culture and PCR is shown in Table 3. There were no signif-
icant differences in culture proportions or PCR detection of 3 main
otopathogens between phases, with H. influenzae the dominant
pathogen in MEF in both. In Phase 2, 18 MEF specimens (5%) were
culture positive forP2 organisms with 12/18 having H. influenzae
as one of the organisms present. In Phase 1, 11 MEF (4%) were pos-
itive for P2 organisms with all having H. influenzae as one of the
organisms.
In Phase 2, 13 children (6%) grew Alloiococcus otitidis (6 bilater-
ally) compared with 33 children (10% and 11 bilaterally) in
Phase 1.
3.5. Microbiology: nasopharyngeal carriage
Culture results for otopathogens isolated from NP specimens
are shown in Table 4. A small proportion of NP samples from chil-
dren undergoing VT surgery were not available in both phases due
to failed collection or loss of specimen (3% Phase 1 and 1% Phase 2).
The overall proportion of pathogens carried remained constant.
Table 4
Nasopharyngeal carriage of bacteria in children undergoing ventilation tube surgery compared with non-otitis prone group; differences between time periods Phase 1, 2011 &
Phase 2, 2014.
Ventilation tube surgical group p-value Non-otitis prone comparisons p-value
Phase 1: 2011 Phase 2: 2014 VT group Phase 1: 2011 Phase 2: 2014 Comparison group
NP cultured from children recruited n/N 316/325 316/319 137/137 154/154
NP culture positive for P1 pathogens 275 (87%) 281 (88%) NS 105 (77%) 116 (75%) NS
H. influenzae 195 (62%) 195 (61%) NS 58 (42%) 65 (42%) NS
S. pneumoniae
Vaccine serotypea
Non vacc serotypeb
135 (43%)
36 (11%)
98 (31%)
156 (49%)
5 (1%)
151 (48%)
NS
P =< 0.001
P =< 0.001
40 (29%)
11 (8%)
29(21%)
49 (32%)
0 (0%)
49 (32%)
NS
P =< 0.001
P =< 0.05
M. catarrhalis 181 (57%) 170 (53%) NS 68 (50%) 76 (49%) NS
Single pathogen only
H. inf
S. pn
M. cat
102 (32%)
57 (18%)
13 (4%)
32 (10%)
105 (33%)
51 (16%)
30 (9.5%)
24 (7.6%)
NS 58 (42%)
21 (15%)
5 (4%)
32 (23%)
58 (38%)
23 (15%)
9 (5.8%)
26 (17%)
NS
Two pathogens
S. pn + H. inf
S. pn + M. cat
M. cat + H. inf
128 (41%)
30 (9%)
41 (13%)
57 (18%)
112 (35%)
30 (10%)
32 (10%)
50 (16%)
NS 33 (24%)
11 (8%)
10 (7%)
12 (9%)
43 (28%)
8 (5%)
16 (10%)
19 (12%)
NS
NP = nasopharyngeal sample.
H. inf = Haemophilus influenzae; S. pn = Streptococcus pneumoniae; M. cat =Moraxella catarrhalis.
a Vaccine serotype = S. pneumoniae serotypes included in PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F) for Phase 1 & PCV 10 (PCV7 plus 1,5,7F) for Phase 2.
b Non vaccine serotype = S. pneumoniae serotypes not included in PCV7 for Phase 1 & not included in PCV10 for Phase 2.
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moniae serotypes in both groups in the second phase and an
increase in non-vaccine serotypes between time periods.
Higher rates of NP carriage of H. influenzae or S. pneumoniae
occurred in children undergoing VT insertion compared with
non-otitis prone children in both phases.
3.6. Molecular differentiation of Haemophilus species
In both phases, isolates of Haemophilus (281 in Phase 1 and 375
in Phase 2) were further characterised by molecular methods to
show 96% were H. influenzae and 4% were H. haemolyticus. Of the
H. influenzae 99% were non-typeable in Phase 1 and 97% in Phase
2. Capsulated isolates from Phase 2 were further typed as type e
(7 isolates) and type f (4 isolates). In Phase 2, 14 children had
H. haemolyticus identified in the NP alone, with 1 child having
the organism concurrently identified in MEF.
3.7. Streptococcus pneumoniae serotyping
Thirty-two isolates of S. pneumoniae from MEF from 25 children
were available for serotyping in Phase 1 and 29 isolates from 25
children in Phase 2 (Fig. 1). Serotype 19A was the dominant sero-
type detected in MEF in Phase 2. Amongst serotypes isolated from0
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Fig. 1. Comparison of Streptococcus pneumoniae serotypes isolated from miNP (Fig. 2), changes were seen in the VT group and non-otitis prone
children between phases. In Phase 1 serotype 19F was the most
common serotype followed by 19A in both groups. In Phase 2
19A was the most common serotype identified in NP followed by
6C and 35B. There were differences in serotypes carried between
children undergoing VT surgery and those in the comparison
group. In the VT group 19A was most common followed by 35B
and 6C whereas in the comparison group 6C was most common
followed by 19A.
3.8. Antibiotic susceptibilities
Overall there was no change in the antibiotic susceptibility pro-
file of the 3 otopathogens between time periods. H. influenzae iso-
lates from MEF and NP were commonly amoxycillin sensitive
(Phase 1: 80% and Phase 2: 84%) and infrequently had detectable
b-lactamase (10% and 8%). There was no significant change for M.
catarrhalis susceptibility between phases with the majority having
detectable b-lactamase present conferring resistance to amoxy-
cillin (Phase 1: 87%; Phase 2: 95%) with resistance to other antibi-
otics uncommon.
For S. pneumoniae reduced susceptibility to penicillin
(MIC > 0.06) was found in almost 1/3 of isolates in both time peri-
ods (64/206 (31%) Phase 1 and 75/228 (33%), Phase 2). Amongst23B 15C 9N 35B 3 35F 19F 31 38 23F
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E.J. Best et al. / Vaccine 34 (2016) 3840–3847 3845S. pneumoniae with penicillin resistance (MICP 2 lg/mL), 15/16
(94%) were multidrug-resistant (resistant to P3 additional antibi-
otic classes) which was also unchanged compared with Phase 1
(19/21 (90%) of S. pneumoniae with penicillin resistance were also
multidrug-resistant).
In Phase 1 the majority of penicillin resistant and multidrug-
resistant isolates were serotype 19F (18/19 isolates) with the
remaining one being serotype 19A. In Phase 2 where 19F was an
uncommon serotype, the majority of the penicillin and
multidrug-resistant isolates were serotype 19A (12/15; 80%).
4. Discussion
Our study provides the most comprehensive evaluation of the
microbiology of otitis media to date New Zealand children. We
have been unable to demonstrate changes in the microbiology of
OM and NP carriage in otitis-prone children, between a cohort
vaccinated with PCV7 and a later cohort vaccinated with
PHiD-CV10. The persisting dominance of NTHi in middle ear fluid
and NP carriage in our otitis prone children, without change in
the rates of detection or ratios when compared with other
otopathogens, suggests that the introduction of the PHiD-CV10
vaccine has not impacted on NTHi in established ear disease in
this age group. This has implications for vaccine development in
combating NTHi as an upper respiratory pathogen.
Strengths of our study include the high enrolment through both
phases of the study, with over 75% recruitment of all children
undergoing ventilation tube procedure captured from NZ’s two
major cities. Our cohort time periods were recruited with identical
inclusion criteria and seasonally matched, yet separated by 3 years
with a full 2 year period following PHiD-CV10 introduction to the
national schedule. This enabled the Phase 2 cohort to be >90%
exclusively PHiD-CV10 exposed. Both demographic data and risk
factors examined in our cohorts were consistent over the two time
periods.
Increasing experience with PHiD-CV10 has shown effectiveness
against invasive pneumococcal disease (IPD) in children in Finland
[30], Brazil [31], Netherlands [32], and Quebec, Canada [33,34]. A
randomised controlled trial in South America involving over
20,000 children demonstrated efficacy of PHiD-CV10 in reducing
radiologic pneumonia in vaccine recipients by over 20% and
vaccine efficacy of 16% against clinical AOM. However the smallnumbers of presentations of OM and very small numbers of MEF
cultures limited assessment of impact on OM of the H. influenzae
component of AOM in that study [35]. More recently a reduction
in incidence of both AOM presentations and pneumonia at a large
children’s hospital in Iceland has been observed after introduction
of PHiD-CV10 to their national schedule [36].
The lack of change on rate of carriage of NTHi in our study fol-
lowing PHiD-CV10 introduction reflect findings in other studies
[18,37]. Lack of effect of PHiD-CV10 to prevent carriage of
H. influenzae implies also that there will be no indirect (herd)
protection from H. influenzae carriage. Our data does show near
elimination in carriage of PHiD-CV10 vaccine-type S. pneumoniae
serotypes in 3 years following PHiD-CV10 introduction.
H. haemolyticus is a non-pathogenic commensal organism
which is difficult to distinguish from H. influenzae by conventional
microbiology [25,38]. H. haemolyticus appears to be infrequently
carried in the NP of our population and was only detected in 2
MEF samples. Our data demonstrates that H. influenzae remains
the most common otopathogen carried in the nasopharynx in
otitis-prone children; and in both cohorts over 95% of H. influenzae
isolates were truly NTHi. We have also demonstrated the persisting
NP carriage of Haemophilus is not due to H. haemolyticus replace-
ment. However the complexity of NTHi and its evolution under
selective pressure continues to be elucidated and increasingly
other variants are recognised [39]. Ongoing monitoring of the
molecular diversity within NTHi carriage isolates in the era of
new generation pneumococcal conjugate vaccines continues to
be important for future understanding of NTHi carriage and disease
[40].
S. pneumoniae was least commonly detected otopathogen by
culture or PCR in MEF or by culture of NP, with the overall detec-
tion rate not changed between Phases. However both the nasopha-
ryngeal and MEF isolates demonstrated a change in serotype
prevalence in the PHiD-CV10 era with increased proportions of ser-
otype 19A, 6C and 35B. In Phase 1, the PCV-7 vaccinated cohort,
19F (a PCV7 vaccine serotype) remained frequently detected in
NP carriage for both otitis-prone and comparison groups despite
PCV7 introduction 3 years prior and high vaccine coverage (95%
of Phase 1 cohort received at least 3 doses of PCV). Infrequent
detection of 19F in both NP and in MEF in Phase 2 suggests effec-
tiveness of PHiD-CV10 against this serotype. However serotype
19A is considered a cross-reactive serotype with 19F and
3846 E.J. Best et al. / Vaccine 34 (2016) 3840–3847PHiD-CV10 licensing studies showing improved immunogenicity
in infants receiving PHiD-CV10 who produced cross reactive
antibodies to 19A when compared with PCV7 vaccinated infants
[41,42]. Post licensure effectiveness analyses from both Brazil
and Finland support some cross protection against IPD from
serotype 19A [30,31]. Our data does not support PHiD-CV10
preventing carriage of non-vaccine serotype 19A. In New Zealand
IPD is notifiable and national data demonstrates decline of IPD
due to 19F in children aged <2 years since PCV introduction.
Although IPD has declined, serotype 19A is now the commonest
serotype causing IPD in children aged <2 years (7/23 IPD cases in
under 2 year olds in 2013 and 12/24 in 2014) [13]. Subsequently
PHiD-CV10 has been replaced by PCV13 in the NZ national
immunisation schedule 2014.
Our data demonstrates a shift from 19F to 19A as the serotype
currently associated with multidrug-resistance and penicillin
resistance [43,44]. Both children undergoing VT surgery and those
in non-otitis prone groups had high rates of antibiotic pre-
treatment (>50% had received antibiotics in last month) which
was consistent between time periods. High antibiotic exposure
seen in our cohort and recognised in New Zealand [45] is known
to impact on pneumococcal population genomics and capsular
switching [46]. Therefore both high antibiotic exposure along with
apparent lack of effectiveness of PHiD-CV10 in preventing carriage
of serotype 19A, may be responsible for our observed increase in
serotype 19A.
A small number of completely unvaccinated children and chil-
dren who received an incomplete course of PHiD-CV10 or had
received one or more doses or PCV13 were included in the study.
However the vast majority of the Phase 2 cohort received at least
3 doses of PHiD-CV10. In addition our cohort was collected at least
2 years after implementation of PHiD-CV10 which means indirect
(herd) effects are likely on those non-vaccinated or partly vacci-
nated children.
Our data was not designed to look at incidence of rAOM nor
OME. As others have suggested using ventilation tube insertion
as an indirect measure of vaccine impact is fraught with difficulty,
as it is prone to influence from local guidelines, surgical referral
patterns, parent or cultural acceptance of surgical procedure and
inequity in socioeconomic status [47,48].
Our study was powered to detect a decrease of 20% in NTHi
infection; it is possible a smaller reduction may have occurred
below the detection limits of our study. However the frequency
of NTHi detection in MEF in our study was greater than initially
accounted for in our sample size calculations.
As NTHi is clearly an important pathogen in established ear dis-
ease, there is need for head to head comparison through ran-
domised controlled trial to determine impact on otitis media
with PHiD-CV10 and other pneumococcal conjugate vaccines
[49]. For NZ assessment of AOM and OME presentations both to
hospital and family practitioners are also warranted to look at
pneumococcal vaccination impact on young children, acknowledg-
ing children presenting for VT insertion are a small proportion of
overall children suffering from ear disease.
5. Conclusion
This large multicentre multiphase study represents the most
comprehensive national data collection on the microbiology of
middle ear disease and nasopharyngeal carriage in New Zealand
children. We were unable to identify any significant differences
between the two cohorts in the rates of identification of NTHi
carriage or presence in middle ear fluid collected during VT inser-
tion. The introduction of PHiD-CV10 vaccine appears to have had
no significant impact on the microbiology of MEF in children
receiving VT or nasopharyngeal carriage in New Zealand children.Role of funding source
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